Display options
Cite
van Eimeren T, Antonini A, Berg D, et al. Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. Alzheimers Dement (Amst). 2019;11:301-309doi: 10.1016/j.dadm.2019.01.011.
van Eimeren, T., Antonini, A., Berg, D., Bohnen, N., Ceravolo, R., Drzezga, A., Höglinger, G. U., Higuchi, M., Lehericy, S., Lewis, S., Monchi, O., Nestor, P., Ondrus, M., Pavese, N., Peralta, M. C., Piccini, P., Pineda-Pardo, J. �. �., Rektorová, I., Rodríguez-Oroz, M., Rominger, A., Seppi, K., Stoessl, A. J., Tessitore, A., Thobois, S., Kaasinen, V., Wenning, G., Siebner, H. R., Strafella, A. P., & Rowe, J. B. (2019). Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. Alzheimer's & dementia (Amsterdam, Netherlands), 11301-309. https://doi.org/10.1016/j.dadm.2019.01.011
van Eimeren, Thilo, et al. "Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System." Alzheimer's & dementia (Amsterdam, Netherlands) vol. 11 (2019): 301-309. doi: https://doi.org/10.1016/j.dadm.2019.01.011
van Eimeren T, Antonini A, Berg D, Bohnen N, Ceravolo R, Drzezga A, Höglinger GU, Higuchi M, Lehericy S, Lewis S, Monchi O, Nestor P, Ondrus M, Pavese N, Peralta MC, Piccini P, Pineda-Pardo JÁ, Rektorová I, Rodríguez-Oroz M, Rominger A, Seppi K, Stoessl AJ, Tessitore A, Thobois S, Kaasinen V, Wenning G, Siebner HR, Strafella AP, Rowe JB. Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. Alzheimers Dement (Amst). 2019 Apr 02;11:301-309. doi: 10.1016/j.dadm.2019.01.011. eCollection 2019 Dec. PMID: 30984816; PMCID: PMC6446052.
Copy Download .nbib Format: NLM
Share it on

Alzheimers Dement (Amst). 2019 Apr 02;11:301-309. doi: 10.1016/j.dadm.2019.01.011. eCollection 2019 Dec.

Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System.

Alzheimer's & dementia (Amsterdam, Netherlands)

Thilo van Eimeren, Angelo Antonini, Daniela Berg, Nico Bohnen, Roberto Ceravolo, Alexander Drzezga, Günter U Höglinger, Makoto Higuchi, Stephane Lehericy, Simon Lewis, Oury Monchi, Peter Nestor, Matej Ondrus, Nicola Pavese, María Cecilia Peralta, Paola Piccini, José Ángel Pineda-Pardo, Irena Rektorová, María Rodríguez-Oroz, Axel Rominger, Klaus Seppi, A Jon Stoessl, Alessandro Tessitore, Stephane Thobois, Valtteri Kaasinen, Gregor Wenning, Hartwig R Siebner, Antonio P Strafella, James B Rowe

Affiliations

  1. Multimodal Neuroimaging, Department of Nuclear Medicine, Medical Faculty and University Hospital, University of Cologne, Cologne, Germany.
  2. German Centre for Neurodegenerative Diseases (DZNE), Bonn-Cologne, Germany.
  3. Department of Neuroscience, University of Padua, Padua, Italy.
  4. Department of Neurology, UKSH, Campus Kiel, Christian-Albrechts-University, Kiel, Germany.
  5. Division of Nuclear Medicine, Department of Radiology, University of Michigan, and VAMC, Ann Arbor, MI, USA.
  6. Department of Neurology, University of Michigan, Ann Arbor, MI, USA.
  7. VAMC, Ann Arbor, MI, USA.
  8. Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  9. Forschungszentrum Jülich, INM-2, Jülich, Germany.
  10. German Centre for Neurodegenerative Diseases (DZNE), and Technical University Munich, Department of Neurology, Munich, Germany.
  11. National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
  12. Institut du Cerveau et de la Moelle épinière - ICM, Centre de NeuroImagerie de Recherche - CENIR, ICM Team "Movement Investigations and Therapeutics", Sorbonne Universités, Inserm U1127, CNRS UMR, Paris, France.
  13. Brain & Mind Centre, Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
  14. Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
  15. Department of Radiology, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
  16. Queensland Brain Institute, University of Queensland, Brisbane, QLD, Australia.
  17. Mater Hospital, South Brisbane, QLD, Australia.
  18. AXON Neuroscience CRM Services SE, Bratislava, Slovak Republic.
  19. Newcastle Magnetic Resonance Centre & Positron Emission Tomography Centre, Newcastle University, Newcastle upon Tyne, United Kingdom.
  20. Center for Medical Education and Clinical Research, Section of Neurology, Buenos Aires, Argentina.
  21. Department of Medicine, Imperial College London, London, United Kingdom.
  22. hmCINAC, University Hospital HM Puerta del Sur, CEU-San Pablo University, Móstoles, Madrid, Spain.
  23. First Department of Neurology - Faculty of Medicine and CEITEC MU, Masaryk University, Brno, Czech Republic.
  24. Department of Neurology, Clinica Universidad de Navarra, Pamplona, Spain.
  25. Department of Nuclear Medicine, Inselspital, Universitätsspital Bern, Bern, Switzerland.
  26. Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
  27. Pacific Parkinson's Research Centre, University of British Columbia, Vancouver, Canada.
  28. Department of Medical, Surgery, Neurological, Metabolic and Aging Sciences, University of Campania, "L. Vanvitelli", Caserta CE, Italy.
  29. Université de Lyon, Université Claude Bernard Lyon 1, Faculté de Medecine Lyon Sud Charles Merieux, Lyon, France.
  30. Hospices Civils de Lyon, Hopital Neurologique Pierre Wertheimer, Neurologie C, Lyon, France.
  31. CNRS, Institut des Sciences Cognitives, Bron, France.
  32. Department of Neurology, University of Turku, Turku, Finland.
  33. Division of Clinical Neurosciences, Turku University Hospital, Turku, Finland.
  34. Division of Clinical Neurology, Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
  35. Danish Research Centre for Magnetic Resonance, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.
  36. E.J. Safra Parkinson Disease Program, Toronto Western Hospital & Krembil Research Institute, UHN, Toronto, Ontario, Canada.
  37. Research Imaging Centre, Campbell Family Mental Health Research Institute, CAMH, Toronto, Ontario, Canada.
  38. University of Toronto, Toronto, Ontario, Canada.
  39. Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.

PMID: 30984816 PMCID: PMC6446052 DOI: 10.1016/j.dadm.2019.01.011

Abstract

INTRODUCTION: Therapeutic strategies targeting protein aggregations are ready for clinical trials in atypical parkinsonian disorders. Therefore, there is an urgent need for neuroimaging biomarkers to help with the early detection of neurodegenerative processes, the early differentiation of the underlying pathology, and the objective assessment of disease progression. However, there currently is not yet a consensus in the field on how to describe utility of biomarkers for clinical trials in atypical parkinsonian disorders.

METHODS: To promote standardized use of neuroimaging biomarkers for clinical trials, we aimed to develop a conceptual framework to characterize in more detail the kind of neuroimaging biomarkers needed in atypical parkinsonian disorders, identify the current challenges in ascribing utility of these biomarkers, and propose criteria for a system that may guide future studies.

RESULTS: As a consensus outcome, we describe the main challenges in ascribing utility of neuroimaging biomarkers in atypical parkinsonian disorders, and we propose a conceptual framework that includes a graded system for the description of utility of a specific neuroimaging measure. We included separate categories for the ability to accurately identify an intention-to-treat patient population early in the disease (Early), to accurately detect a specific underlying pathology (Specific), and the ability to monitor disease progression (Progression).

DISCUSSION: We suggest that the advancement of standardized neuroimaging in the field of atypical parkinsonian disorders will be furthered by a well-defined reference frame for the utility of biomarkers. The proposed utility system allows a detailed and graded description of the respective strengths of neuroimaging biomarkers in the currently most relevant areas of application in clinical trials.

Keywords: Biomarker; CBD; CBS; Harmonization; MRI; MSA; Multicentric; Multisite; Neurodegeneration; Neuroimaging; PET; PSP; Trials

References

  1. J Int Neuropsychol Soc. 2002 Mar;8(3):448-60 - PubMed
  2. Neurobiol Aging. 2003 Mar-Apr;24(2):197-211 - PubMed
  3. Ann Emerg Med. 2003 Aug;42(2):298-303 - PubMed
  4. Neurology. 2004 Feb 24;62(4):591-600 - PubMed
  5. Nature. 2006 Oct 19;443(7113):768-73 - PubMed
  6. Mov Disord. 2007 Nov 15;22(15):2141-8; quiz 2295 - PubMed
  7. Brain. 2008 May;131(Pt 5):1362-72 - PubMed
  8. Neurology. 2008 Aug 26;71(9):670-6 - PubMed
  9. Lancet Neurol. 2009 Mar;8(3):270-9 - PubMed
  10. Ann Neurol. 2011 Aug;70(2):327-40 - PubMed
  11. Brain Pathol. 2013 Jan;23(1):28-33 - PubMed
  12. Lancet Neurol. 2013 Mar;12(3):264-74 - PubMed
  13. Parkinsonism Relat Disord. 2014 Aug;20(8):840-4 - PubMed
  14. Neuropathol Appl Neurobiol. 2015 Feb;41(1):3-23 - PubMed
  15. Brain. 2015 Aug;138(Pt 8):2293-309 - PubMed
  16. Rev Neurol (Paris). 2016 Jan;172(1):14-26 - PubMed
  17. Neurology. 2016 Feb 9;86(6):566-76 - PubMed
  18. Mov Disord. 2017 Feb;32(2):181-192 - PubMed
  19. Mov Disord. 2017 Jun;32(6):853-864 - PubMed
  20. J Nucl Med. 2017 Sep;58(9):1357-1359 - PubMed
  21. Mov Disord. 2017 Jul;32(7):955-971 - PubMed
  22. Neurobiol Aging. 2017 Sep;57:1-7 - PubMed
  23. Lancet Neurol. 2017 Jul;16(7):552-563 - PubMed
  24. Mov Disord. 2017 Oct;32(10):1356-1364 - PubMed
  25. Brain. 2018 Feb 1;141(2):550-567 - PubMed
  26. Brain. 2018 Feb 1;141(2):568-581 - PubMed
  27. Mov Disord Clin Pract. 2018 Oct 09;5(6):586-596 - PubMed

Publication Types

Grant support